CIS is First in Capital Region to Use Bioconvertible Filter for the Prevention of Pulmonary Embolism

Bioconvertible IVC Filter Zachary cropped

Pictured from left to right are Shane Castille, Boston Scientific rep, Dr. Deepak Thekkoott, CIS interventional cardiologist, and Eric Rome, cath lab director.

ZACHARY, LA– Cardiovascular Institute of the South (CIS) is the first in the Capital Region to use the Sentry Bioconvertible Inferior Vena Cava (IVC) Filter to protect against pulmonary embolism without the need for a second retrieval procedure. The first use was performed by CIS interventional cardiologist Dr. Deepak Thekkoott at Lane Regional Medical Center.

The leading cause of preventable mortality in U.S. hospitals, pulmonary embolism is a condition in which one or more arteries in the lungs become blocked by a blood clot. The use of IVC filters is commonly used in patients with contraindications to anticoagulation therapy—for example, those who have been injured or who are at high risk of bleeding—or patients with a high risk of embolism occurrence. However, the benefit of this new filter manufactured by Boston Scientific is that it is bioconvertible. It filters for 60 days and then the absorbent filament opens up to leave an unobstructed lumen, eliminating the need for a retrieval procedure, and reducing the risk of potential complications and risks from long-term filters.

“We are proud to offer this new advanced treatment for our patients at risk for pulmonary embolism,” said Dr. Thekkoott. “It is effective in preventing pulmonary embolism while eliminating certain risks of traditional filters. This ultimately means better care and outcomes for our patients here at CIS.”

Click below to schedule an appointment at a CIS location near you.

Request an Appointment


Latest News

CIS Staff

Written by CIS Staff